Hester Biosciences Ltd - 524669 - Announcement Under Regulation 30 Of Listing Regulations - Disclosure On Amendments In Loan Agreement Of Hester Africa
Hester Biosciences' subsidiary, Hester Africa, restructured its loan from Gates Foundation. The outstanding debt was reduced from USD 12 million to USD 5 million, with accrued interest waived and no further interest charged, significantly improving liquidity.
May 20 2026 16:05:00
Hester Biosciences Ltd - 524669 - Intimation Of Submission Of The Reclassification Application Under Regulation 31A Of Listing Regulations
Hester Biosciences submitted an application seeking "No Objection" from BSE and NSE for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from the promoter to the public shareholding category. This is in accordance with Regulation 31A of SEBI (LODR) Regulations.
May 20 2026 10:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Hester Bio's Q4 FY26 consolidated revenue increased by 22% and PAT surged 174%. The company's Poultry Healthcare division recorded 41% growth and secured licensing for the H9N2 Avian Influenza vaccine. Net debt reduced to Rs.70 crore, lowering debt-to-equity to 0.19 times, reflecting improved financial health.
May 18 2026 09:05:00
Hester Biosciences Ltd - 524669 - Announcement Under Regulation 30 (LODR) - Corporate Presentation
Hester Biosciences released its Corporate Presentation for FY26. The presentation highlights strong financial growth with consolidated net profit increasing by 99% to Rs.57.48 crore and consolidated revenue rising by 7% to Rs.332.60 crore.
May 15 2026 17:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Hester Biosciences informed that the audio recording of its earnings conference call for the financial results of Q4 FY26 is now available on the company website for investor access.
May 15 2026 16:05:00
Hester Biosciences Ltd - 524669 - Disclosure On Board Approval For Re-Classification Request Under Regulation 31A Of SEBI Listing Regulations
Hester Biosciences board approved the request for re-classification of promoters Mr. Ravin Gandhi and Ms. Bela Gandhi to the 'public' shareholder category. This re-classification is contingent upon receiving a No Objection Certificate from the stock exchanges.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Intimation Of Receipt Of Requests For Reclassification From The 'Promoters' To The 'Public' Category In Accordance With Regulation 31A Of SEBI Listing Regulations
Hester Biosciences received requests from two promoters, Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake), for reclassification of their shareholdings from 'Promoter' to 'Public' category. This formalizes their passive investment status and lack of management involvement.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Change in Management
Hester Biosciences re-appointed Ms. Priya Gandhi as Executive Director for a three-year term, effective October 28, 2026. She is the daughter of CEO & MD Rajiv Gandhi and has been instrumental in driving the company's strategic direction.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Hester Biosciences reported strong Q4 FY26 consolidated results, with revenue growing 22% YoY and net profit soaring 974% YoY to INR 165.46 million. The board also recommended a dividend of INR 11 per equity share for FY26.
May 15 2026 12:05:00
Hester Biosciences Ltd - 524669 - Board Meeting Outcome for Outcome Of Board Meeting Held On 15 May 2026
Hester Biosciences reported Q4 FY26 cons. revenue of ₹100.11 crores (up 22% YoY) and net profit of ₹16.55 crores (up 974% YoY). The board also recommended a ₹11 dividend per share for FY26 and divested 43.81% stake in subsidiary TLPL.
May 15 2026 11:05:00
Read More